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E-cadherin is a major adherens junction protein of
epithelial cells, with a central role in cell-cell adhesion
and cell polarity. Newly synthesized E-cadherin is tar-
geted to the basolateral cell surface. We analyzed target-
ing information in the cytoplasmic tail of E-cadherin by
utilizing chimeras of E-cadherin fused to the ectodo-
main of the interleukin-2a (IL-2a) receptor expressed in
Madin-Darby canine kidney and LLC-PK1 epithelial
cells. Chimeras containing the full-length or membrane-
proximal half of the E-cadherin cytoplasmic tail were
correctly targeted to the basolateral domain. Sequence
analysis of the membrane-proximal tail region revealed
the presence of a highly conserved dileucine motif,
which was analyzed as a putative targeting signal by
mutagenesis. Elimination of this motif resulted in the
loss of Tac/E-cadherin basolateral localization, pin-
pointing this dileucine signal as being both necessary
and sufficient for basolateral targeting of E-cadherin.
Truncation mutants unable to bind b-catenin were cor-
rectly targeted, showing, contrary to current under-
standing, that b-catenin is not required for basolateral
trafficking. Our results also provide evidence that
dileucine-mediated targeting is maintained in LLC-PK1
cells despite the altered polarity of basolateral proteins
with tyrosine-based signals in this cell line. These re-
sults provide the first direct insights into how E-cad-
herin is targeted to the basolateral membrane.
E-cadherin is expressed on the lateral membranes of epithe-
lial cells where it accumulates as a major component of the
adherens junction. The cadherins in adherens junctions have
central roles in establishing and maintaining cell-cell adhesion
and cell polarity in epithelia and participate in morphogenesis
during development (1–4). The continual expression and func-
tion of E-cadherin is important in its role as a tumor suppressor
and the loss of E-cadherin function contributes to tumor inva-
sion and progression in carcinomas (5).
Mature, human E-cadherin is a 728-amino acid, single pass
transmembrane protein (6). The E-cadherin ectodomain is in-
volved in Ca21-dependent homotypic binding to E-cadherins on
adjacent cell membranes, and its cytoplasmic tail is involved in
a series of protein interactions providing a link to the actin
cytoskeleton. The cytoplasmic tail of E-cadherin is bound di-
rectly to b-catenin or plakoglobin, and thereby to a-catenin and
actin (reviewed in Ref. 2). The binding site for b-catenin has
been mapped by deletion mutagenesis to the distal 76 amino
acids of the carboxyl terminus of E-cadherin (7), with critical
residues found in the last 30 amino acid domain (8). Aside from
its participation as a member of the cadherin-bound adherens
junction complex, b-catenin is involved in the Wnt signaling
pathway through its interactions with a cytoplasmic adenom-
atous polyposis coli complex and with the Lef/Tcf transcription
factors in the nucleus (reviewed in Ref. 9).
Epithelial cells are morphologically and functionally polar-
ized with distinct complements of cell surface proteins and
lipids at the apical or basolateral poles. Maintenance of this
polarity requires that newly synthesized proteins are sorted
and targeted to specific membrane domains (10–12). Sorting of
proteins to the apical domain of polarized cells occurs via lipid
raft interactions or through oligosaccharides (13–15), whereas
specific amino acids motifs act as sorting signals to target
membrane proteins to the basolateral cell surface (reviewed in
Ref. 16). For example, tyrosine-based motifs target the low
density lipoprotein receptor to the basolateral domain of polar-
ized cells (17), whereas a dileucine motif is utilized by other
proteins, like the Fc receptor (18). Both types of signals can also
be used to direct endocytosis from the plasma membrane, al-
though the structural requirements for each pathway may
differ (19–22). Yet other amino acid motifs can be used by
selected proteins for basolateral targeting (23–25). Previous
studies on adhesion molecules have defined a dileucine signal
that functions in the basolateral targeting of the Lutheran
glycoprotein (26) and a similar dihydrophobic signal in CD44
(27). The basolateral targeting of neural cell adhesion molecule
(N-CAM) has been attributed to a cytoplasmic tail sequence
without classic motif homology (23). Detailed information and
further insights are needed into how other classes of adhesion
proteins, including cadherins, are sorted and trafficked in po-
larized cells.
Recently, the polarized epithelial cells of the pig kidney
LLC-PK1 line have been distinguished as having aspects of
inverted polarity. Roush et al. (28) noted that some typically
basolateral proteins, such as the H,K-ATPase b subunit, are
delivered to the apical pole of LLC-PK1 cells. Mis-sorting of
basolateral proteins in LLC-PK1 cells led to subsequent anal-
ysis of their AP-1 adaptor complexes. Most polarized epithelial
cells express a special m1B subunit, which directs polarized
sorting to the basolateral surface (29). It has now been shown
that LLC-PK1 cells express a m1A subunit but not the m1B
subunit and that this results in aberrant sorting of proteins
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with tyrosine-based signals, a defect that can be overcome by
expression of recombinant m1B protein (30). Cadherin staining
in LLC-PK1 cells appears to be basolateral (31), although the
trafficking of these proteins in this cell line has not been stud-
ied in detail.
The correct placement of E-cadherin on the plasma mem-
brane is required from an early stage to help establish and
maintain cell polarity (32). The mechanisms that mediate the
sorting and polarized delivery of E-cadherin to the surface have
not been elucidated. Previous studies have shown that b-cate-
nin binds to E-cadherin early in the biosynthetic pathway,
implying that the two proteins, and perhaps others, are trans-
ported to the cell surface together as a complex (33). More
recently, it was suggested that b-catenin plays an essential role
in the trafficking of E-cadherin, based on observations that
mutagenized proteins, with reduced binding to b-catenin, were
not efficiently delivered to the surface (34). It has also been
previously noted that the cytoplasmic tail of E-cadherin does
contain motifs with homology to known targeting signals (34,
35), which could potentially function to guide its trafficking. In
this study we set out to test putative signals in the cytoplasmic
tail of E-cadherin for possible basolateral targeting informa-
tion. Our experiments also addressed the role of b-catenin in
this targeting. We utilized a series of chimeras to express the
E-cadherin cytoplasmic tail, or mutagenized versions thereof,
using Tac (the a subunit of the IL-2 receptor) as an ectodomain
marker. Tac is a 273-amino acid protein that has previously
been used as a reporter protein for trafficking studies (36, 37).
These constructs were expressed in MDCK1 cells, in which the
basolateral surface expression of E-cadherin is well estab-
lished, and in another epithelial cell line LLC-PK1 cells. Using
these model systems we have identified a positive targeting
signal in E-cadherin that is responsible for basolateral deliv-
ery. Our results provide new insights into the trafficking of
E-cadherin and its accessory proteins (catenins), and the find-
ings are also significant to our understanding of cell polarity
and sorting pathways in epithelia.
EXPERIMENTAL PROCEDURES
Cell Culture—Madin-Darby canine kidney (MDCK) and pig kidney
(LLC-PK1) cell lines were grown and passaged as described previously
(38) in Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.,
Grand Island, NY) supplemented with 10% fetal calf serum and 2 mM
glutamine in 5% CO2 and 95% air.
Antibodies—Mouse monoclonal antibodies (Transduction Laborato-
ries, Lexington, KY) raised against a conserved region of the cytoplas-
mic domain of human E-cadherin and against b-catenin were used; Tac
was recognized using a mouse monoclonal antibody (B-B10, BIO-
SOURCE International, Camarillo, CA) and a rabbit polyclonal anti-
body directed against the green fluorescence protein (GFP) (Molecular
Probes Inc., Eugene, OR) was also used for staining. Secondary anti-
bodies included Cy3-conjugated sheep anti-mouse and goat anti-rabbit
IgGs (Jackson ImmunoResearch Labs, West Grove, PA) and a horse-
radish peroxidase-conjugated sheep anti-mouse IgG (AMRAD, Victoria,
Australia).
cDNA Construction and Expression—Chimeric fusions between hu-
man E-cadherin cDNAs and the cDNA encoding for Tac were generated
in the pCDNA3 expression vector. Molecular cloning techniques were
performed according to Sambrook et al. (39), using reagents from New
England BioLabs (Beverly, MA). All constructs were confirmed by DNA
sequencing. cDNAs encoding the transmembrane plus cytoplasmic do-
mains (residues 554–728), the cytoplasmic tail (residues 578–728), or
the amino-terminal half of the cytoplasmic tail (578–653) of human
E-cadherin were amplified using PCR with specific oligonucleotide
primers. E-cadherin residue numbers correspond to the mature protein
as defined previously (6). The oligonucleotide primers contained restric-
tion endonuclease sites allowing generation of in-frame fusions with the
Tac cDNA. Cloning the respective PCR products into pCMV-IL2R (40)
using the HindIII and XbaI sites generated the pCMV-Tac/Ecad-(578–
728) and pCMV-Tac/Ecad-(578–653) plasmids. The entire Tac/E-cad-
herin cDNA constructs were then subcloned into the pCDNA3 expres-
sion vector (Invitrogen, Carlsbad, CA) that also encodes for the
neomycin selection marker. The resulting constructs were termed Tac/
Ecad-(578–728) and Tac/Ecad-(578–653). To generate the Tac/Ecad-
(554–728) plasmid, an EcoRV restriction endonuclease site was intro-
duced using PCR at the end of the extracellular domain of the Tac cDNA
within pCDNA3. This modification altered residue 239 of the Tac cDNA
from an Asp to a Gln. The final plasmid was generated by cloning the
E-cadherin PCR product into the EcoRV and XbaI sites.
E-cadherin-GFP encodes the full-length E-cadherin sequence with
the green fluorescence protein (GFP) fused to the carboxyl terminus of
the cytoplasmic domain. Initially, a SacII restriction endonuclease site
was introduced at the carboxyl terminus of the full-length cDNA of
E-cadherin. This was achieved by the PCR amplification of the entire
E-cadherin cDNA using specific oligonucleotide primers using
pCDNA3-hECad (41) as a template. The 39-primer included the SacII
site and a XbaI site. The resulting PCR product was digested with
SgrA1 and XbaI and subcloned into pCDNA3-hECad using the same
sites. The open reading frame of GFP was amplified by PCR using
specific oligonucleotide primers and pEGFP-N1 (CLONTECH, Palo
Alto, CA) as a template. The 59-primer contained a SacII site that
allowed the resulting PCR product to be cloned into the SacII site
introduced into in the carboxyl terminus of E-cadherin.
Mutagenesis of the two leucine residues at positions 587 and 588 of
human E-cadherin to alanines was performed using oligonucleotide
cloning. The construct pCMV-Tac/Ecad-(578–728) was digested with
HindIII and XbaI to remove a 55-bp fragment that included the codons
for the dileucine residues. The digested plasmid was then ligated with
the annealed, phosphorylated, synthetic oligonucleotides 59-AGCTTC-
GTCGACGCGCGGTGGTCAAAGAGCCCGCAGCACCCCCAGAGGAT-
GACAC3-9 and 59-CCGGGTGTCATCCTCTGGGGGTGCTGCGGGCTC-
TTTGACCACCGCGCGTCGACGA39. These complementary oligonu-
cleotides contain a 59-HindIII end and a 39-XbaI end, as well as codons
encoding for LRRRAVVKEPAAPPEDD (altered residues are under-
lined). The resulting construct was termed Tac/Ecad-(578–728)DS1.
For transfection and expression of cDNAs, sub-confluent LLC-PK1 or
MDCK cells were transfected with plasmid DNA (2 mg) in complex with
LipofectAMINE Plus reagent (Life Technologies, Inc., Gaithersburg,
MD) according to the manufacturer’s guidelines. For stably expressing
lines, transfected cells were passaged and maintained in media con-
taining G418 (Geneticin, Life Technologies, Inc.); cells were kept under
selection for 7–10 days and then plated at low density for ring cloning
of surviving cells. Clonal cell lines were generated and then assessed by
indirect immunofluorescence and immunoblotting to select lines with
different levels of recombinant protein expression.
Indirect Immunofluorescence—Confluent monolayers of cells grown
on glass coverslips or on Transwell polycarbonate filters (Corning
Costar, Cambridge, MA) were generally fixed in 4% paraformaldehyde
in PBS for 90 min and then permeabilized in PBS containing 0.1%
Triton X-100 for 5 min. In one experiment LLC-PK1 cells were fixed in
ice-cold methanol for 10 min. Cells were then incubated sequentially
with primary antibody (1 h) and then secondary antibodies (30 min)
using PBS containing bovine serum albumin (Sigma Chemical Co., St.
Louis, MO) as a blocking buffer. Cells were mounted on slides in
PBS/glycerol (50/50) containing 1% n-propyl-galate. For some experi-
ments, cells were treated with 10 mM cycloheximide (Sigma), which was
added to the medium for various times up to 4 h prior to fixation. Cells
on coverslips were examined by epifluorescence using an Olympus
Provis AX-70 microscope, and images were collected with a CCD300ET-
RCX camera (DageMTI, Michigan City, IN) using National Institutes of
Health IMAGE software. Cells growing on Transwell filters were ex-
amined using a Bio-Rad MRC-600 confocal laser-scanning microscope
mounted on a Zeiss Axioskop, and XY and XZ sections were generated
using Bio-Rad MRC-600 CoMOS software.
Immunoprecipitation and Immunoblotting—Confluent monolayers
of transfected MDCK and LLC-PK1 cells were solubilized in cold RIPA
buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS, 0.15 NaCl, 5 mM
EDTA, 25 mM Tris-HCl, pH 7.4) containing protease inhibitors (Roche
Molecular Biochemicals, Germany) on ice. Post-nuclear supernatants
were incubated with the Tac antibody for 2 h and then with washed
protein G beads (Sigma) for a further 2 h. Precipitates were recovered
by centrifugation then washed through several rounds of RIPA buffer
1 The abbreviations used are: MDCK, Madin-Darby canine kidney
cells; GFP, green fluorescence protein; IL-2R, interleukin-2 receptor;
LLC-PK1, pig kidney proximal tubular epithelial cell line; PAGE, poly-
acrylamide gel electrophoresis; PBS, phosphate-buffered saline; PCR,
polymerase chain reaction; Tac, IL-2Ra chain; RIPA, radioimmune
precipitation buffer; bp, base pair(s); CMV, cytomegalovirus.
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and 20 mM Tris-HCl (pH 7.4) prior to solubilization in concentrated
SDS-PAGE sample buffer. Proteins in cell extracts and immunoprecipi-
tates were separated on 8% SDS-PAGE reducing gels and then trans-
ferred to polyvinylidene difluoride Immunobilon-P membranes (Milli-
pore, Bedford, MA) and stained with 0.1% Coomassie Brilliant Blue to
ensure even protein transfer and protein loading. Membranes were
immunoblotted by sequential incubations in primary antibody, horse-
radish peroxidase-conjugated secondary antibody followed by chemilu-
minescence detection with Supersignal West Pico (Pierce Chemical Co.,
Rockford, IL). Different luminescence exposures were collected and
exposures in the linear range were used.
Surface Biotinylation—Confluent monolayers of LLC-PK1 cells sta-
bly expressing Tac/Ecad-(578–728) or Tac/Ecad-(578–653) grown on
filters were incubated in media containing 1.5 mg/ml Sulfo-NHS-SS-
biotin (Pierce), applied to either the apical or basal side of the filter, for
60 min on ice. Filters were then washed several times in cold PBS
before cells were scraped off and lysed in cold RIPA buffer. Soluble cell
fractions were incubated with streptavidin beads (Sigma) in RIPA
buffer, pH 7.4, for 2 h with rotation. Beads were then washed in several
rounds of RIPA buffer and 20 mM Tris-HCl (pH 7.4). Biotinylated
proteins bound to the streptavidin beads and unlabeled proteins in the
supernatants were analyzed by SDS-PAGE, immunoblotting, and den-
sitometry to quantitate the relative amounts of biotinylated Tac/Ecad
proteins.
RESULTS
Basolateral Targeting of E-cadherin—E-cadherin is deliv-
ered to the basolateral surface of polarized MDCK cells, where
it gives a typical and widely documented staining pattern using
specific antibodies (Fig. 1a). The same antibody did not stain
E-cadherin in paraformaldehyde-fixed LLC-PK1 cells (Fig. 1c),
but it did produce cell surface staining of E-cadherin in meth-
anol-fixed LLC-PK1 cells (31 and Fig. 1b). Hence E-cadherin is
expressed endogenously in both cell lines and is found in a
polarized distribution. A tagged construct of human GFP-E-
cadherin was expressed in MDCK cells, generating a clear
basolateral surface staining pattern with GFP antibodies,
showing that GFP-E-cadherin is targeted in a manner analo-
gous to the endogenous protein (Fig. 1d). GFP-E-cadherin was
also expressed in epithelial LLC-PK1 cells, where it was also
targeted in a polarized fashion to the basolateral membrane
(Fig. 1e).
Targeting of Tac/E-cadherin Chimeras—For targeting stud-
ies we utilized chimeras consisting of the ectodomain of Tac
fused to the cytoplasmic tail of E-cadherin (Fig. 2A). Chimeric
cDNAs expressed in epithelial cells all produced proteins of the
expected molecular masses (Fig. 2B). Tac typically localizes to
the apical membrane in polarized cells (Ref. 36 and Fig. 3, a
and b), therefore, any basolateral signal in the E-cadherin
cytoplasmic domain is predicted to redirect Tac from apical to
basolateral membranes. cDNAs for Tac alone or chimeric pro-
teins were transfected into MDCK and LLC-PK1 cells, and
clonal, stably transfected cell lines were selected. Antibodies
against Tac were used to detect the chimeric proteins and
determine their localization by indirect immunofluorescence
and confocal microscopy.
Chimeras containing the full cytoplasmic tail of E-cadherin
were expressed and found to redirect Tac to the basolateral
domain in both MDCK and LLC-PK1 cells. Both Tac/Ecad-
(578–728) and Tac/Ecad-(554–728), which additionally en-
codes the transmembrane domain of E-cadherin, were localized
by epifluorescence and by confocal imaging to the basolateral
membranes of MDCK and LLC-PK1 cells (Fig. 3). Thus the
presence or absence of the E-cadherin transmembrane domain
had no effect on targeting. These results indicate that the
Tac/E-cadherin chimeras are efficiently synthesized and trans-
ported to the cell surface and that the cytoplasmic tail of
E-cadherin contains positive sorting information, capable of
rerouting Tac to a basolateral trafficking pathway. MDCK cells
expressing Tac/Ecad-(578–728) showed no concomitant loss of
endogenous E-cadherin staining on the basolateral surface (not
shown), suggesting that the sorting and targeting machinery in
FIG. 1. Localization of E-cadherin.
MDCK and LLC-PK1 cells were generally
fixed with paraformaldehyde and labeled
with a mouse monoclonal antibody to lo-
calize endogenous E-cadherin by immu-
nofluorescence. a, E-cadherin staining in
MDCK cells on cell boundaries is at the
basolateral domain; b, in LLC-PK1 cells
fixed in methanol, there is typical baso-
lateral surface staining; c, in LLC-PK1
cells fixed in paraformaldehyde the
E-cadherin antibody gave no staining.
GFP-E-cadherin is localized by the GFP
antibody on the basolateral membrane of
transfected MDCK cells (d) and LLC-PK1
cells (e). There is also some intracellular,
perinuclear staining of newly synthesized
GFP-E-cadherin in LLC-PK1 cells (ar-
rows). Bar, 2.5 mm.
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these cells has not been saturated or subverted by the overex-
pressed protein.
Basolateral Targeting Mediated by the Membrane-proximal
E-cadherin Tail—As the first step in a more detailed analysis
of the cytoplasmic tail of E-cadherin, a truncation mutant was
created to effectively bisect the cytoplasmic tail, leaving only
the membrane-proximal portion of the tail fused to Tac. The
resulting Tac/Ecad-(578–653) construct was expressed in
MDCK and LLC-PK1 cells (Fig. 4). Immunofluorescence stain-
ing and confocal analysis showed that it was distributed in a
polarized fashion. There was no staining of apical membranes
when antibody was applied to either unpermeabilized cells (not
shown) or permeabilized cells, however, there was staining of
the basolateral membranes in LLC-PK1 and MDCK cells ex-
pressing Tac/Ecad-(578–653) (Fig. 4, a and c). Thus, chimeras
containing either the full-length tails or only the membrane-
proximal tails are trafficked similarly and have the same po-
larized surface distribution.
We noted that, in cells from several different clones stably
expressing Tac/Ecad-(578–653), there was intracellular stain-
ing of Tac/Ecad-(578–653) in a perinuclear, Golgi-like pattern
in addition to basolateral surface staining (Fig. 4a). This pat-
tern was not regularly seen in cell lines expressing chimeras
with full-length tails (Tac/Ecad-(554–728) or Tac/Ecad-(578–
728)). LLC-PK1 cells expressing Tac/Ecad-(578–653) were
treated with cycloheximide to stop protein synthesis and fixed
and stained at various times after addition of the drug. There
was a sequential loss of intracellular staining followed at lon-
ger times by a diminution of cell surface staining. Fig. 4 shows
that after 2 h of treatment, all of the intracellular staining had
disappeared, leaving only staining of Tac/Ecad-(578–653) at
the basolateral surface. From this it was concluded that intra-
cellular staining in these cells represents a transient accumu-
lation of newly synthesized Tac/Ecad-(578–653) in the biosyn-
thetic pathway and that the membrane-proximal chimera is
transported to the basolateral membrane at a slower rate than
Tac/Ecad-(578–728).
The targeting of Tac/Ecad-(578–653) was finally tested us-
ing a surface biotinylation assay to measure and quantify its
appearance on the plasma membrane domains of confluent,
polarized cells. Cell surface biotinylation was performed on cell
lines stably expressing Tac/Ecad-(578–728) and Tac/Ecad-
(578–653). Addition of biotin reagents to the basal sides of the
monolayers labeled most of the Tac/Ecad-(578–728) and Tac/
Ecad-(578–653) proteins, whereas from the apical side almost
no labeling occurred in either case (see Table I). Together these
results show that a chimeric protein, containing only the mem-
brane-proximal half of the E-cadherin cytoplasmic tail, has
sufficient information to direct efficient sorting and targeting
to the basolateral cell surface, albeit perhaps at a slower rate
than constructs with the full-length cytoplasmic tail.
A Dileucine Motif Is Responsible for Basolateral Targeting of
E-cadherin—Sequence analysis of the membrane-proximal E-
cadherin tail encoded by the region in Tac/Ecad-(578–653)
revealed the presence of two putative targeting motifs. Se-
quence alignment of members of the type I cadherins, of which
E-cadherin is the prototype, and type II cadherins (42), re-
vealed that a dileucine motif at position 587 is highly conserved
across species and preserved in almost all members of the
family (Fig. 5A). To test this dileucine motif for targeting in-
formation, the leucines at positions 587 and 588 were changed
to alanines in the chimeras encoding the full-length tail and
membrane-proximal tail, using oligonucleotide cloning. The re-
sulting mutated chimeras, termed Tac/Ecad-(578–728)DS1 and
Tac/Ecad-(578–653)DS1, were transfected into LLC-PK1 and
MDCK cells and then localized by immunofluorescence (Fig.
5B). Tac/Ecad-(578–728)DS1 and Tac/Ecad-(578–653)DS1
were localized at the apical surfaces of transfected LLC-PK1
and MDCK cells, in patterns similar to the apical Tac (Fig. 3, a
and 3b) and distinct from the basolateral non-mutated chime-
ras. Thus removal of the dileucine motif at 587 from the E-
cadherin cytoplasmic domain resulted in a loss of basolateral
targeting information. We conclude that this motif is a positive
sorting signal for the basolateral membrane localization of
E-cadherin and that it is necessary to direct sorting. The high
level of conservation of this dileucine motif throughout the
cadherins family further suggests that it has a key functional
role. A second potential targeting signal of the type NPXY is
present in the sequence of Tac/Ecad-(578–653). This tyrosine-
based signal at position 600 was not tested here and is not
considered a likely candidate for targeting, based on experi-
mental data from another study (34) and our observation that
FIG. 2. A, diagrammatic representation of chimeras. Chimeras were
made by fusing amino-terminal regions of Tac, encompassing the ex-
tracellular domain and transmembrane domain to the full-length car-
boxyl-terminal cytoplasmic tail of E-cadherin (shaded) (Tac/Ecad-(578–
728)). In some constructs the transmembrane domain of Tac was
replaced with that of E-cadherin (Tac/Ecad-(554–728)). In Tac/Ecad-
(578–653) the E-cadherin tail was truncated leaving only the mem-
brane-proximal region. B, extracts of MDCK (lane 1) and LLC-PK1 cells
(lanes 2–5) were probed by immunoblotting with the E-cadherin anti-
body to detect Tac/Ecad chimeras. Proteins of the expected molecular
weight were detected for each of the Tac/Ecad chimeras (Tac/Ecad-
(578–728), 72 kDa; Tac/Ecad-(554–728), 72 kDa; Tac/Ecad-(578–653),
62 kDa; Tac/Ecad-(578–728)DS1, 72 kDa (see also Fig. 5)).
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the motif is not conserved in cadherins across different species.
Binding of b-Catenin—b-Catenin is known to bind to the
cytoplasmic tail of E-cadherin early in the biosynthetic path-
way and has previously been implicated in trafficking to the
cell surface (34). Therefore, Tac/E-cadherin chimeras were
tested for their ability to bind to b-catenin. The interaction of
endogenous E-cadherin in MDCK cells with b-catenin was
demonstrated by co-immunoprecipitation of the two proteins
using an E-cadherin antibody (Fig. 6A). Tac/Ecad-(578–728)
was immunoprecipitated with the Tac antibody from extracts
of transfected MDCK and LLC-PK1 cells, and b-catenin co-
precipitating in the complex was detected by immunoblotting.
In extracts of both MDCK and LLC-PK1 cells, b-catenin was
bound to Tac/Ecad-(578–728) (Fig. 6B). This finding suggests
that the full-length cytoplasmic tail in Tac/Ecad-(578–728) is
correctly folded and processed in a manner conducive to effec-
tive trafficking and surface delivery.
The membrane-proximal Tac/Ecad-(578–653) construct is
missing the carboxyl-terminal b-catenin binding domain, and
co-immunoprecipitation experiments confirm that, as expected,
b-catenin was not co-precipitated with this truncated chimeric
protein (Fig. 6B). Endogenous E-cadherin and chimeras with
full-length E-cadherin tails were able to efficiently bind and
co-immunoprecipitate b-catenin (Fig. 6, A and B). Deletion of
the 587 dileucine targeting signal had no effect on binding of
b-catenin, which was efficiently co-precipitated with Tac/Ecad-
(578–728)DS1 (Fig. 6B). The correct basolateral targeting of Tac/
Ecad-(578–653) in the absence of bound b-catenin now demon-
strates that b-catenin is not essential for basolateral sorting and
targeting in either MDCK or LLC-PK1 cells. The complexing of
b-catenin with newly synthesized E-cadherin may be required for
other roles in biosynthetic processing or trafficking, for instance,
the loss of b-catenin binding may account for the increased
FIG. 3. Localization of Tac/E-cad-
herin chimeras. Immunofluorescence
staining of Tac or Tac/E-cadherin chime-
ras in stably transfected cell lines using
the Tac antibody. Upper views show cross
sections of monolayers; lower views in
each panel represent XZ sections of filter-
grown cells. MDCK (a) and LLC-PK1 (b)
cells overexpressing full-length Tac on
their apical domains; c, Tac/Ecad-(554–
728) expressed in LLC-PK1 cells is local-
ized on the basolateral membrane. The
Tac/Ecad-(578–728) construct is also on
the basolateral domains of transfected
LLC-PK1 cells (d) and MDCK cells (e).
Bars, 2.5 mm.
FIG. 4. Immunofluorescence local-
ization of the membrane-proximal
chimera. LLC-PK1 (a, b) and MDCK (c)
cells overexpressing Tac/Ecad-(578–653)
were stained with the Tac antibody.
The truncated chimera encoding only the
membrane-proximal tail localized to the
basolateral domains of confluent cells.
There was also some intracellular, pe-
rinuclear staining in untreated cells (a)
that disappeared after 2 h of treatment
with cycloheximide (b). Bars, 2.5 mm.
TABLE I
Cell surface subjected to biotinylation
Surface expression of Tac/Ecad constructs. Cells stably overexpress-
ing Tac/Ecad-(578–728) and Tac/Ecad-(578–653) were incubated with
Sulfo-NHS-SS-biotin added to apical or basal side. Biotinylated pro-
teins were isolated and analyzed by immunoblotting and densitometry
to calculate the proportion of each construct accessed from each side of
the cell layer.
Basal Apical
%
Tac/Ecad-(578–728) 95 5
Tac/Ecad-(578–653) 96 4
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intracellular accumulation and apparently slower trafficking of
the Tac/Ecad-(578–653) mutants.
DISCUSSION
E-cadherin is one of the proto-typical polarized membrane
proteins in epithelia. It is delivered to the basolateral mem-
brane and is concentrated in adherens junctions where it par-
ticipates in cell-cell adhesion. To address how E-cadherin is
trafficked and targeted in polarized cells, we made use of Tac/
E-cadherin chimeras expressed in two epithelial cell lines. Our
findings show that chimeras containing full-length or trun-
cated cytoplasmic tails of E-cadherin were effectively sorted
and trafficked to the basolateral surface domain in MDCK and
LLC-PK1 cells. Furthermore, this polarized targeting was lost
after deletion of a single, dominant targeting motif in the
proximal region of the tail. Three main conclusions emerged
from these experiments; (i) that a single dileucine motif at 587
is able to convey basolateral targeting information in Tac/E-
cadherin chimeras and that this signal is necessary for baso-
lateral sorting; (ii) that LLC-PK1 cells are able to correctly sort
and traffic E-cadherin using a dileucine-based mechanism, in
contrast to proteins sorted by tyrosine-based signals that are
mis-trafficked in these cells, and (iii) that b-catenin is not
required for basolateral targeting and surface delivery of
E-cadherin.
Chimeras containing the full cytoplasmic tail of E-cadherin,
Tac/Ecad-(578–728) and Tac/Ecad-(554–728), were efficiently
targeted and trafficked to the basolateral domain of MDCK and
LLC-PK1 cells in a similar manner to that of endogenous E-
cadherin or GFP-E-cadherin in either cell line. The Tac ectodo-
main did not interfere with the intracellular trafficking or
processing in the full-length tail constructs, because there was
no evidence of less efficient membrane delivery or retention
within the secretory pathway. The transmembrane domain has
been implicated in mediating lateral association and adhesive
strength of cadherins in the plasma membrane, without affect-
ing surface delivery (43). Amino acid sequences within trans-
membrane segments can, however, be involved in targeting as
exemplified by the apical targeting signal in one of the trans-
membrane segments of the a-subunit of the gastric parietal
H,K-ATPase (44). Our experiments directly tested the E-cad-
herin transmembrane domain, with the finding that this region
of the protein has no role in basolateral targeting nor in sorting
or membrane delivery of Tac/E-cadherin chimeras. Overall the
results obtained with the Tac/E-cadherin chimeras point to the
cytoplasmic tail of E-cadherin as having positive basolateral
sorting information, in keeping with many other type I mem-
brane proteins.
The correct basolateral targeting of the Tac/Ecad-(578–653)
construct first indicated that the membrane-proximal tail re-
gion alone is sufficient for membrane targeting and that distal
regions of the tail are not required for targeting or surface
delivery. In our hands, mutants with the truncated tail of
E-cadherin, Tac/Ecad-(578–653), were processed, targeted,
and delivered to the basolateral cell surface, albeit at a slower
rate than constructs with the full cytoplasmic tail. Transient
accumulation of Tac/Ecad-(578–653) in the biosynthetic path-
way, seen as intracellular staining in LLC-PK1 cells, indicated
that it was trafficked less efficiently than the full-length tail.
Partial accumulation of Tac/Ecad-(578–653) was similarly
noted in MDCK cells, although the truncated tail mutants did
eventually reach the cell surface. Our findings are in contrast
to those of a previous study in which a series of chimeras
representing truncation mutants of the E-cadherin tail fused to
a GP-2 ectodomain, were found to be very poorly trafficked (34).
Only about 10% of the truncated GP-2 chimeric proteins in that
study reached the surface of MDCK cells and were randomly
sorted, whereas the majority of the proteins were blocked or
degraded early in the secretory pathway (34). On the basis of
the correct targeting and delivery of Tac/Ecad-(578–653),
which contains similar tail regions to some of the mutants in
the previous study, we hypothesize that the poor processing
and trafficking of those chimeras may have been due to the
influence of the GP-2 ectodomain rather than being a function
of E-cadherin trafficking or accessory proteins (see below).
The membrane-proximal tail region of E-cadherin has been
implicated in a number of functions. Cadherin clustering and
adhesive strength were shown to be affected by mutations in
the membrane-proximal region of the C-cadherin tail (45).
Binding of the p120ctn protein has also been shown to occur in
this region (45, 46), and some of the amino acid sequences
mapped by two-hybrid analysis, as being specifically involved
in the binding of p120ctn (47), overlap with the dileucine tar-
geting signal identified in this study. It is therefore likely that
this membrane-proximal region of the tail is involved in mul-
tiple, temporally regulated protein interactions that are impor-
tant, initially for E-cadherin transport, and then for adhesive
function at the cell surface. Positive sorting mediated by the
Tac/Ecad-(578–653) membrane-proximal tail allowed us to fo-
cus on putative sorting signals in this region. The dileucine
motif at 587 was chosen here as a candidate targeting signal.
Despite being in the non-conserved region of the tail, sequence
alignments revealed that the dileucine consensus motif is
highly conserved throughout cadherins of type I or II cadherin
FIG. 5. A, sequence alignment of cadherins with conserved cytoplas-
mic tails (type I and II families as defined by Nollet et al. (42)). Se-
quence alignment of the membrane-proximal tail regions of cadherin
family members, including E-cadherin (cadherin 1), N-cadherin (cad-
herin 2), and VE-cadherin (cadherin 5). A dileucine motif at position 587
(shaded) in E-cadherin (cadherin 1) is highly conserved across members
of the family and is relatively close to the transmembrane domain
(underlined) in the membrane-proximal region of the tail. B, targeting
of dileucine deletion mutants. MDCK and LLC-PK1 cells expressing
Tac/Ecad-(578–728)DS1 or Tac/Ecad-(578–653)DS1 were stained with
the Tac antibody. Both constructs with deleted dileucine motifs, now
show apical targeting. Prominent apical staining only, is now seen in
both cell lines expressing Tac/Ecad-(578–728)DS1 or Tac/Ecad-(578–
653)DS1. Bars, 2.5 mm.
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families (42). We therefore predict that this dileucine will func-
tion to target all similar transmembrane cadherins to basolat-
eral domains of polarized epithelial cells. Cadherins in which
the dileucines are not conserved include cadherins 5 (VE-cad-
herin) and 20. The glycosyl phosphatidylinositol-anchored cad-
herin 13 (T-cadherin), as expected, does not have a dileucine
motif (48).
Our experimental results, therefore, confirmed that the
dileucine motif in E-cadherin does function as a targeting sig-
nal. Replacing the leucines with alanines in the full-length or
truncated tail constructs resulted in a complete loss of basolat-
eral targeting. The dileucine signal in E-cadherin has an acidic
amino acid cluster on its carboxyl-terminal side that is highly
conserved throughout dileucine-containing cadherins and is
similar to targeting motifs in other basolateral proteins, includ-
ing furin (49), invariant chain (50), and low density lipoprotein
receptor (22). In some cases, such as for furin, these acidic
clusters have been shown to be important for the function of
dileucine signals in basolateral targeting (49). Dileucine sig-
nals functioning in endocytosis typically have an acidic residue
at the 24 position (D/EXXXLL) (21, 51, 52). In contrast, the
cadherin dileucine signal typically has a basic lysine or argi-
nine in the 24 position. It is, therefore, unlikely that this motif
will also function as an endocytosis motif.
There are additional motifs sharing consensus with target-
ing signals encoded in the E-cadherin tail. Tyrosines at two
places within the tail, one being in the membrane-proximal
region and another at the carboxyl terminus, were deleted in a
previous study and found to have no role in targeting of E-
cadherin (34). There is a combined YXXf tyrosine and
dileucine motif (673–677), similar in structure to the overlap-
ping motif, which has been shown to be responsible for baso-
lateral targeting of the pIg F receptor in MDCK cells (53).
There is also a motif belonging to the YXXf group, with a
tyrosine at the second X position (705–708). Both of these latter
signals are adjacent to, or within, the b-catenin binding domain
and are thus predicted to be sequestered when E-cadherin is
complexed to b-catenin. The possibility remains open, however,
that any of these additional signals might be uncovered during
dynamic protein interactions and therefore could act as target-
ing signals during further trafficking of surface E-cadherin.
One or more of these signals could, for instance, target E-
cadherin to clathrin-coated vesicles for endocytosis and recy-
cling (35) after it reaches the basolateral plasma membrane.
Overall, analysis of targeting motifs points to a dileucine signal
rather than tyrosine-based signals being responsible for the
polarized sorting and basolateral delivery of E-cadherin.
Both MDCK and LLC-PK1 cell lines form polarized epithelial
monolayers in culture that show patent basolateral trafficking
and secretion of soluble proteoglycans (54, 55). Due to the
reported inverse polarity of LLC-PK1 (28, 30), it was of interest
to also analyze E-cadherin trafficking in these cells. Our find-
ings verify that E-cadherin is trafficked correctly to the baso-
lateral surface of the LLC-PK1 cells, and we show that this
targeting, as in MDCK cells, is directed by a dileucine motif.
This provides new evidence to confirm that basolateral target-
ing via dileucine-based mechanisms functions correctly in LLC-
PK1 cells. The correct targeting of endogenous E-cadherin,
GFP-E-cadherin, and Tac/Ecad constructs suggests that
dileucine-based sorting is fully sufficient to direct basolateral
trafficking in these cells. LLC-PK1 cells are defective in target-
ing of tyrosine-based motifs due to the absence of the m1B chain
(30). However, the sorting of dileucine motifs occurs through
interaction with the b subunits of the adaptor complex (56),
allowing correct sorting of proteins such as T cell receptor
sub-unit (CD3g), Fc receptor, and E-cadherin. The correct tar-
geting of endogenous E-cadherin and Tac/Ecad constructs in
LLC-PK1 cells acts as further evidence that this targeting does,
in fact, rely on dileucine rather than tyrosine motifs. The full
nature of the adaptor complexes or that required for post-Golgi
transport of E-cadherin in either LLC-PK1 or MDCK epithelial
cells have yet to be characterized.
Finally, the current study also provides new insights into the
role of b-catenin in E-cadherin trafficking. b-Catenin is a cyto-
plasmic protein with affinity for the cytoplasmic tail of E-
cadherin, it binds to E-cadherin early in the biosynthetic path-
way, forming a stable complex that is transported to the cell
surface (33). Chen and colleagues (34) concluded that b-catenin
is required for the biosynthetic processing and trafficking of
E-cadherin, based on a correlation between deletion of residues
within or near the b-catenin binding domain and loss of surface
delivery in GP-2-E-cadherin chimeras and other constructs.
However, our current results suggest a different scenario. We
showed that full-length tail chimeras co-precipitated b-catenin
in similar proportion to that seen in endogenous E-cadherin-b-
catenin complexes. Upon expressing the Tac/Ecad-(578–653)
chimera, which clearly did not bind b-catenin, we found it was
correctly targeted and transported to the cell surface, suggest-
ing that b-catenin is not required for sorting or delivery under
these conditions. b-Catenin may have a role in facilitating or
optimizing the transport, processing, or folding of newly syn-
thesized E-cadherin. All of these factors might well contribute
to the slower processing and transient accumulation of Tac/
Ecad-(578–653) that we noted in the absence of b-catenin.
Recent biophysical and biochemical analyses further suggest
that b-catenin binding might also serve to protect the E-cad-
FIG. 6. Co-immunoprecipitation of b-catenin. A, proteins immunoprecipitated from untransfected MDCK cells with a monoclonal antibody
to E-cadherin were probed by immunoblotting with the E-cadherin antibody (top) or with a b-catenin antibody (bottom). Proteins at 120 and 92 kDa,
respectively, were detected. B, the Tac antibody was used to immunoprecipitate chimeras from transfected LLC-PK1 cells. The b-catenin antibody
was then used for immunoblotting supernatants (SN lanes 1, 3, and 5) and immunoprecipitates (IP lanes 2, 4, and 6). b-Catenin was co-precipitated
with Tac/Ecad-(578–728) (lane 2) but not with the truncated Tac/Ecad-(578–653) chimera (lane 4). Deletion of the dileucine targeting motif
(Tac/Ecad-(578–728)DS1) did not affect co-precipitation of b-catenin (lane 6).
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herin tail from degradation (57). Our finding, that b-catenin is
not required for basolateral targeting or surface delivery, sheds
new light on b-catenin as having a role in facilitating, but not
directing, cadherin trafficking.
The polarized targeting of E-cadherin is of seminal impor-
tance to the maintenance of epithelial polarity and function.
Targeting signals and mechanisms must ensure the accurate
basolateral delivery of newly synthesized E-cadherin and of
internalized and recycled E-cadherin for its incorporation into
adherens junctions. In this study we demonstrate one such
mechanism, basolateral sorting directed via a dileucine signal.
Future studies will address specific roles for additional signals
and perhaps for some of the accessory proteins in cadherin/
catenin complexes.
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